<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03344159</url>
  </required_header>
  <id_info>
    <org_study_id>20170694</org_study_id>
    <nct_id>NCT03344159</nct_id>
  </id_info>
  <brief_title>Spironolactone Therapy in Chronic Stable Right HF Trial</brief_title>
  <acronym>STAR-HF</acronym>
  <official_title>Spironolactone Therapy in Chronic Stable Right HF Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of
      spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity
      and right heart function and remodeling in patients with chronic right heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase 4, single center, randomized, double blind, placebo-controlled trial
      evaluating the safety, tolerability and mechanistic effects of spironolactone, an aldosterone
      antagonist, on neurohormonal activity and remodeling in patients with chronic right heart
      failure (RHF).

      RHF is one of the most important predictors of prognosis in many cardiac disease states
      including pulmonary hypertension (PH), and left heart failure. Sympathetic nervous system
      activation plays an important role in the development and progression of heart failure. It
      remains to be determined whether there is a role for neurohormonal therapy in chronic right
      HF, but evidence points to the role of sympathetic nervous system stimulation and activation
      of the renin-angiotensin and aldosterone system as a contributor to progressive right heart
      failure.

      The study will determine if treatment with spironolactone is associated with reduction in
      right ventricular wall stress. In addition, the study aims to evaluate the effects of
      spironolactone on cardiac sympathetic activity assessed by HED retention on PET imaging, and
      global autonomic function assessed by heart rate variability.

      Approximately 50 patients with RHF will be randomized to receive either spironolactone daily
      or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>STAR-HF is a phase 4 single center, randomized, placebo controlled trial comparing spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated to matching placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients will be blinded to study treatment for the duration of the study. Clinicians will also be blinded to study drug assignment. Evaluation of all study results will be done blinded to treatment randomization. Because of the double-blind design, safety laboratory tests, and monitoring of potential side effects will be performed for each participant for the duration of the trial, regardless of the treatment arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Ventricular Wall Stress</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>To determine if treatment with spironolactone is associated with a significant reduction in RV ventricular wall stress, as reflected by a reduction in serum NT-proBNP, in patients with chronic stable right HF when compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Sympathetic Nervous System Activity</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Changes in cardiac sympathetic activity, as assessed by an increase in 11[C]-hydroxy-ephedrine (HED) retention by cardiac PET imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Autonomic Nervous System Function</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Heart rate variability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic Sympathetic Activation</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Changes in plasma levels of epinephrine and norepinephrine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Right Ventricle Structure</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Changes in RV end-diastolic and end-systolic size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Right Ventricle Function</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Changes in RV ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Right Ventricle areas of fibrosis</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Changes in RV areas of fibrosis assessed with T1 weighted MR imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events.</measure>
    <time_frame>number of adverse events from baseline to 12 weeks.</time_frame>
    <description>1. incidence of worsening renal function (defined as a change in estimated glomerular filtration rate&gt;30%). 2. Incidence of hyperkalemia (&gt;4.5, 5 or 5.5 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biomarkers of Fibrosis</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Changes in biomarkers of fibrosis (ST2, PIINP, CITB, TIMP1, MMP-9)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Serum Aldosterone</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>changes in plasma levels of aldosterone</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Six Minute walk test</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>Distance a participant can walk in a period of 6 walks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in NYHA function class</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>changes in NYHA functional class.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Right heart failure Severity</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Worsening right HF- defined as need for increase in diuretic dose or open-label initiation of a potassium sparing diuretic, or hospitalization or need for IV diuretics</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Outcomes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hospitalization and/or all cause mortality</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Right-Sided Heart Failure</condition>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Pulmonary Hypertension, Primary, 2</condition>
  <condition>Pulmonary Hypertension, Primary, 3</condition>
  <condition>Pulmonary Hypertension, Primary, 4</condition>
  <condition>Cardiomyopathy Right Ventricular</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic right-sided heart failure will receive spironolactone 12.5mg daily up to a maximum dose of 50 mg daily for a total duration of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with chronic right-sided heart failure will receive placebo daily for a total duration of 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.</description>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo daily for a total of duration of 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82</intervention_name>
    <description>At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.</description>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac MRI (Gadolinium enhanced)</intervention_name>
    <description>At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.</description>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide a personally signed and dated inform consent form.

          -  Male or female â‰¥ 18 years.

          -  Able to comply with all study procedures.

          -  History of right heart failure (RHF) secondary to either:

             i) WHO, group 1 pulmonary arterial hypertension PAH OR ii) WHO group II PH with normal
             LV systolic function OR iii) WHO group III or IV PH OR iv) primary RV cardiomyopathy.

          -  Current NYHA II-IV

          -  RV dysfunction as measured by 2D echocardiogram:

             i)defined as a tricuspid annular plane systolic excursion (TAPSE) &lt;16 mm ii) and /or a
             two dimensional fractional area change &lt;35% on screening echo plus

          -  NT-proBNP&gt;400 pg/ml

          -  Chronic use of diuretics

          -  Clinical stability: defined as no need for increased diuretics, hospitalization or
             emergency room visit 3 months prior to enrollment

        Exclusion Criteria:

          -  Patients on chronic MRA therapy or other potassium sparing diuretics.

          -  Baseline serum potassium&gt;5 ummol/l.

          -  Estimated glomerular filtration rate &lt;30 ml/min.

          -  LV ejection fraction &lt;45%,

          -  Moderate or severe LV diastolic function,

          -  Moderate or severe aortic or valvular disease.

          -  Patients requiring augmentation of diuretics or otherwise not meeting definition for
             clinical stability.

          -  Severe Liver Failure (Child-Pugh Class C)

          -  Claustrophobia or inability lie still in a supine position

          -  Patients with contraindications to either PET or CMR imaging

          -  Pregnancy or lactation.

          -  Unable to provide consent and comply with follow up visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Mielniczuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosemary Dunne, RN</last_name>
    <phone>613 696 7000</phone>
    <phone_ext>19295</phone_ext>
    <email>rdunne@ottawaheart.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jason Zelt, MSc</last_name>
    <phone>613 696 7000</phone>
    <phone_ext>19744</phone_ext>
    <email>jzelt@ottawaheart.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Mielniczuk, MD</last_name>
      <phone>613 696 7274</phone>
      <email>lmielniczuk@ottawaheart.ca</email>
    </contact>
    <contact_backup>
      <last_name>Rosemary Dunne, RN</last_name>
      <phone>613 696 7000</phone>
      <phone_ext>19295</phone_ext>
      <email>rdunne@ottawaheart.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Lisa Mielniczuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rob Beanlands, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Wells, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rob DeKemp, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Pena, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Chandy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vladimir Contreras, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Thornhill, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Zelt, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ottawa Heart Institute Research Corporation</investigator_affiliation>
    <investigator_full_name>Lisa Mielniczuk</investigator_full_name>
    <investigator_title>Director, Heart Failure Program, Medical Co-Director, Pulmonary Hypertension Program</investigator_title>
  </responsible_party>
  <keyword>Mineralocorticoid receptor antagonist</keyword>
  <keyword>Brain natriuretic peptide (BNP)</keyword>
  <keyword>Sympathetic Nervous System</keyword>
  <keyword>Positron Emissions Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Dextrocardia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data with researchers outside of Dr. Mielniczuk's research team.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

